NPS Pharmaceuticals (NPSP)
NPS Pharmaceuticals R&D Expense: 20.20M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NPSP R&D Expense Rankings
| Overall | 21st percentile | 1385 of 1763 |
| Sector | 20th percentile | 328 of 413 in Healthcare |
| Industry | 17th percentile | 124 of 151 in Biotechnology |
NPSP R&D Expense Range, Past 5 Years
| Minimum | 3.998M | Jun 2008 |
| Maximum | 21.56M | Dec 2011 |
| Average | 11.75M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these NPSP related companies
NPSP News
NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 29, 4:10PM Business Wire
May 29, 4:10PM Business Wire
RT @TheEquitiesRoom: EBR: Watchlist/worksheet/4 Trading Ideas: $DECK $CRR $NPSP $LOW $V http://stks.co/3wzM < thanks for sharing
about 8 days ago by 1nvestor
about 8 days ago by 1nvestor
$NPSP Close at highs, nice volume too. Can't figure out why this isn't getting more attention.
about 9 days ago by Random_Walk
about 9 days ago by Random_Walk
$NPSP Nice rebound today after yesterday's selloff. Good volume for a change.
about 13 days ago by Random_Walk
about 13 days ago by Random_Walk
$NPSP http://stks.co/3pss Golden Cross, 50MA cross above the 200MA, breakingout the $7.39 resistance, positive momentum
about 16 days ago by gantosj
about 16 days ago by gantosj
ThinkEquity, Canacord, S&P, Needham all have retiterated buy ratings on $NPSP in last week. Very undervalued considering potential here.
about 24 days ago by Random_Walk
about 24 days ago by Random_Walk
$NPSP 200 Day SMA Cross - Price crossed above 200 day SMA (6.8493). Confirmed by volume.
about 27 days ago by TradeIdeasQuant
about 27 days ago by TradeIdeasQuant
$NPSP 200 Day SMA Cross - Price crossed below 200 day SMA (6.8493). Confirmed by volume.
about 27 days ago by TradeIdeasQuant
about 27 days ago by TradeIdeasQuant
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Awaiting Date for Gattex FDA AdCom Meeting
May 04, 9:25AM Street Insider
May 04, 9:25AM Street Insider
Listen to $NPSP Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3f5z
about 27 days ago by earningscast
about 27 days ago by earningscast
$NPSP No love for $NPSP? Nice breakout today, albeit on low volume. Long from 7.10. Holding. http://chart.ly/2f5qte9
about 33 days ago by Random_Walk
about 33 days ago by Random_Walk
$NPSP http://stks.co/3YQG breaking out the channel testing the upper line and bouncing back, looks good with positive momentum
about 34 days ago by gantosj
about 34 days ago by gantosj
$NPSP Volume perking up. Upcoming catalyst. Approaching breakout. Keep an eye on $NPSP.
about 36 days ago by Random_Walk
about 36 days ago by Random_Walk
$NPSP http://stks.co/3Ogl Trading in a horizontal channel, Bollinger band in a Volatility Squeeze, near term catalyst
about 43 days ago by gantosj
about 43 days ago by gantosj
$NPSP http://stks.co/3LuR consolidating with a move over 7 targetting 7.83, under 6.38 targets 5.50
about 46 days ago by harmongreg
about 46 days ago by harmongreg
$NPSP filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3KmH
about 48 days ago by MarketBrief
about 48 days ago by MarketBrief
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
Mar 07, 4:10PM Business Wire
Mar 07, 4:10PM Business Wire
NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
Feb 29, 8:10AM Business Wire
Feb 29, 8:10AM Business Wire
NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance
Feb 15, 4:30PM Business Wire
Feb 15, 4:30PM Business Wire
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX
Jan 31, 8:04AM Benzinga
Jan 31, 8:04AM Benzinga
NPS Pharma (NPSP) announces FDA acceptance of NDA for Gattex(R) in adult SBS
Jan 31, 8:04AM Street Insider
Jan 31, 8:04AM Street Insider
Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Shares Undervalued
Jan 06, 10:29AM Street Insider
Jan 06, 10:29AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NPSP | 7.93 | -0.17 | -2.10% | 697.49M |
| NPM | 15.24 | +0.03 | +0.20% | |
| NPK | 66.00 | -0.43 | -0.65% | 457.04M |
| NNBR | 7.68 | -0.39 | -4.83% | 136.79M |
| NNA | 2.585 | -0.01 | -0.19% | 104.95M |
| NMT | 15.12 | -0.11 | -0.71% | |
| NMRX | 8.92 | -0.06 | -0.67% | 136.14M |
| NMR | 3.27 | -0.05 | -1.51% | 12.16B |
| NMM | 13.98 | -0.37 | -2.58% | 672.87M |
| NMD | 12.32 | +0.01 | +0.08% |
